Adaltis Receives Important Commitment for Eclectica(TM) Instruments in Mexico

    MONTREAL, April 11 /CNW Telbec/ - Adaltis Inc. (TSX: ADS), an
international in vitro diagnostic (IVD) company, today announced that it has
received an important commitment for its flagship product Eclectica(TM) with a
renowned privately-held laboratory group in Mexico. The agreement provides
that Adaltis will place an initial 20 Eclectica(TM) instruments and will have
a minimum reagent purchase commitment per instrument. Shipment of products is
scheduled to start during the second quarter of 2007. Other terms of the
agreement were not disclosed.
    "This is an important commitment for Adaltis as it validates the
specifications and performance of our Eclectica(TM) instrument following an
extensive two month evaluation by our client. We continue to experience strong
demand since the recent launch of Eclectica(TM) in Mexico and plan on
leveraging our experience to expand into other emerging markets, notably,
China, Turkey, India and Brazil. We look forward to continuing our efforts to
build our presence in these markets as we position Adaltis for long-term
growth in emerging markets," said Mr. Pierre Larochelle, President and Chief
Executive Officer of Adaltis.

    About Eclectica(TM)

    Eclectica(TM) is a bench-top hybrid analyzer allowing for the
consolidation of automation platforms in clinical labs. Eclectica(TM) combines
into a compact, single workstation the ability to perform Immunoassay,
Clinical Chemistry and Plasma Protein tests. It is aimed at small to
medium-sized clinics and laboratories that require low to medium workloads of
particular tests.
    The flat touch-screen color monitor along with the separate
alphanumerical keyboard provides the user with a friendly and fast interface
with the instrument. Eclectica(TM) can be connected with a Laboratory
Information System to directly download and upload data.

    About Adaltis

    Adaltis is an international in vitro diagnostic company that develops,
manufactures and markets diagnostic systems. It aims to leverage its
experience in Europe to become a leading provider of in vitro diagnostic
products in emerging markets, with a particular focus on China.
    With the assistance of its two strategic shareholders, CITIC Pacific
Limited (a large Hong Kong-based conglomerate) and Picchio Pharma Inc. (a
joint venture healthcare investment firm owned by FMRC Family Trust (a trust
of which Dr. Francesco Bellini is a beneficiary), and Power Technology
Investment Corporation, a subsidiary of Power Corporation of Canada), Adaltis
has completed building its manufacturing facility in Shanghai. Now
operational, the production facility manufactures high-quality products in a
low-cost GMP environment, in order to service existing markets in Europe,
while providing a platform to penetrate the high-growth Chinese in vitro
diagnostic market.
    Adaltis is headquartered in Montreal, with offices in China, Hong Kong,
Italy, Germany and Mexico.

    Caution Concerning Forward-Looking Statements

    Certain statements made in this press release, including in particular
the impact of this agreement, and other anticipated market opportunities for
our Eclectica(TM) instrument, are forward-looking statements and are subject
to important risks, uncertainties and assumptions. The Company cautions that,
by their nature, forward-looking statements involve risk and uncertainty and
the Company's actual actions or results could differ materially from those
expressed or implied in such forward-looking statements. The forward-looking
statements contained in this press release represent the expectations of
Adaltis Inc. and its subsidiaries as at the date hereof and accordingly are
subject to change after such date. However, Adaltis Inc. and its subsidiaries
expressly disclaim any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise, except as required by applicable law.
    For additional information with respect to the risks and uncertainties
and other factors that could cause the results or events predicted in these
forward-looking statements to differ materially from actual results or events,
please refer to the Annual Information Form of the Company filed with the
Canadian securities commissions.

For further information:

For further information: please contact: Jacques Deforges, Vice
President, Finance and Chief Financial Officer, Adaltis Inc., (514) 335-9922,
ext. 245,; Eddy Miller, Director, Investor
Relations, Adaltis Inc., (514) 335-9922, ext. 257,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890